STAT Plus: Ron Renaud, biotech’s serial CEO, is ready for a new assignment — and maybe another deal?
Adam’s Take
Insights and opinions from senior biotech writer Adam Feuerstein.
Recent topics include Apellis Pharmaceuticals, Moonlake Immunotherapeutics, PDS Biotech, Rubius Therapeutics, Amylyx Pharmaceuticals and Anavex Life Sciences.
Latest
STAT Plus: After Cassava Alzheimer’s drug fiasco, the FDA must intervene to protect patients
STAT Plus: Why Biohaven will test the FDA’s regulatory limits
STAT Plus: Gene therapy for sickle cell disease remains a tough business model — and may never work
STAT Plus: Alnylam versus BridgeBio: The ATTR-CM debate
STAT Plus: Thoughts, takes, and burning biotech questions as the beginning of the end of the year approaches
STAT Plus: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world
STAT Plus: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet?
All Coverage
advertisement
